Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5758-5765

  Duarte, Rafael F ^a   López Jiménez, Javier ^b   Comely, Oliver A ^c   Laverdiere, Michel ^d   Helfgott, David ^e   Haider, Shariq ^f   Chandrasekar, Pranatharthi ^g   Langston, Amelia ^h   Perfect, John ⁱ   Ma, Lei ^j   Van Lersel, Marlou L P S ^k   Connelly, Nancy ^j   Kartsonis, Nicholas ^j   Waskin, Hetty ^j  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e WEILL CORNELL MEDICAL CENTER   (United States)

^f HAMILTON HEALTH SCIENCES   (Canada)

^g KARMANOS CANCER INSTITUTE   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k MSD   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; ANTIFUNGAL AGENT; TABLET; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; SYSTEMIC MYCOSIS; VOLUME OF DISTRIBUTION AT STEADY-STATE; VOMITING; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; CLINICAL TRIAL; MICROBIOLOGY; MIDDLE AGED; MYCOSES; PHARMACOKINETICS; TABLET; THERAPEUTIC USE;

ANTIFUNGAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; TABLETS; TRIAZOLES;

EID: 84907911359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03050-14     Document Type: Article

References (22)

1. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AH, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. http://dx.doi.org/10.1056/NEJMoa061094.
2. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. http://dx.doi.org/10.1056/NEJMoa061098.
3. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2003. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222. http://dx.doi. org/10.1046/j.1365-2125.2003.01977.x.
4. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966. http://dx.doi.org/10.1128/AAC.01034-08.
5. Pille S, Bohmer D. 1998. Options for artificial nutrition of cancer patients. Strahlenther. Onkol. 174(suppl 3):52-55.
6. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, Saltzman MA. 2006. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50:1881-1883. http: //dx.doi.org/10.1128/AAC.50.5.1881-1883.2006.
7. Vehreschild MJ, Meissner AM, Cornely OA, Maschmeyer G, Neumann S, von Lilienfeld-Toal M, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, Vehreschild JJ. 2011. Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 96:1855-1860. http://dx.doi.org/10.3324 /haematol.2011.049627.
8. Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, Beresford E, Komjathy S. 2009. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 53:4749-4752. http://dx.doi.org/10 .1128/AAC.00889-09.
9. Jang SH, Colangelo PM, Gobburu JV. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119. http://dx.doi.org/10.1038/clpt.2010 .64.
10. Krishna G, Abu Tarif M, Xu an F, Martinho M, Angulo D, Cornely OA. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232. http://dx.doi.org/10.1592 /phco.28.10.1223.
11. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636. http://dx.doi.org/10.1592/phco.27.12.1627.
12. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. http://dx.doi.org/10.1086 /508774.
13. Krishna G, Ma L, Martinho M, O'Mara E. 2012. A single dose phase I study to evaluate the pharmacokinetics of posaconazole new tablet and capsule formulations relative to oral suspension. Antimicrob. Agents Chemother. 56:4196-4201. http://dx.doi.org/10.1128/AAC.00222-12.
14. Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. 2012. Anew solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J. Antimicrob. Chemother. 67:2725-2730. http://dx. doi.org/10.1093/jac/dks268.
15. Shen JX, Krishna G, Hayes RN. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236. http://dx.doi.org/10 1016/j.jpba.2006.06.011.
16. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34. http://dx.doi.org/10.1128/AAC.00705-08.
17. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. 2012. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:2806-2813. http://dx. doi.org/10.1128/AAC.05900-11.
18. Tonini J, Thiebaut A, Jourdil JF, Berruyer AS, Bulabois CE, Cahn JY, Stanke-Labesque F. 2012. Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob. Agents Chemother. 56:5247-5252. http://dx.doi.org/10.1128/AAC.00815-12.
19. Merck & Co. Inc. 2013. Noxafil (posaconazole) oral suspension prescribing information.Merck & Co. Inc., Whitehouse Station, NJ.
20. MSD 2013. Noxafil (posaconazole) oral suspension summary of product characteristics. MSD, Hertfordshire, United Kingdom.
21. Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJ, Krishna G, Ma L, Huyck S, McCarthy MC. 2012. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob. Agents Chemother. 56:2652-2658. http://dx.doi.org/10.1128/AAC.05937-11.
22. Cornely OA, Ullmann AJ. 2011. Lack of evidence for exposure-response relationship of posaconazole used for prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89:351-352. http://dx.doi.org/10.1038 /clpt.2010.261.